Diagnosis, Staging and Treatment of Patients with Colon Cancer

Objectives

Provide a national evidence-based clinical guideline for the diagnosis, staging and treatment of adults aged 18 years or over with suspected or newly diagnosed colon cancer, supporting health professionals and clinical governance across primary and secondary care.[1][2][3]The guideline aims to improve quality, safety, consistency and cost-effectiveness of care by integrating research evidence, clinical expertise and patient values, while reducing unwarranted variation in practice.[4][5]

• Strengthen diagnosis and staging through contrast-enhanced computed tomography of the thorax, abdomen and pelvis, selective liver magnetic resonance imaging, selective positron emission tomography-computed tomography after multidisciplinary discussion, and complete colonic visualisation before surgery where appropriate.[6][7][8]
• Improve surgical and pathological quality through lesion tattooing, adequate lymph-node retrieval and microscopic examination, with a laboratory median of at least 12 nodes, and assessment of pathological risk features after local excision.[9][10][8]
• Support individualised treatment through multidisciplinary assessment of obstructive disease, minimally invasive colectomy by experienced surgeons where suitable, and specialist review before treatment of unresectable metastatic disease except in surgical emergencies.[11][12][13]
• Provide early, continuous and needs-based palliative care, ensuring that patients can access the level of palliative-care expertise appropriate to their needs.[14][15]
• Support centralisation of cancer surgery in designated centres, including the National Cancer Strategy target that 95% of public-hospital cancer surgery be undertaken in approved centres by 2020.[16][5]
• Promote national clinical effectiveness through leadership, publication of standards and guidance, commissioning and quality assurance of National Clinical Guidelines and National Clinical Audit, and alignment with service-delivery priorities.[4]

Implementation

Implement the guideline through hospital multidisciplinary teams, national cancer governance and service planning. Corporate responsibility rests with each hospital Chief Executive Officer, General Manager and Clinical Director, while multidisciplinary team members implement recommendations within their professional disciplines; justified departures based on professional judgement or patient choice should be recorded in the healthcare record.[1][17]The National Cancer Control Programme leads cancer-policy implementation and works with the Health Service Executive, Department of Health, Hospital Groups and cancer centres to support service centralisation, workforce planning, performance review and delivery.[16][18][19]

• Use multidisciplinary team meetings to formally discuss each patient’s case, selected equivocal imaging findings, local-excision specimens and unresectable metastatic disease, with appropriate diagnostic, surgical, oncology, pathology and palliative-care expertise.[16][20][14]
• Develop and implement a National Clinical Effectiveness Committee implementation plan that identifies actions, leads, timescales and intended outcomes; require senior management and multidisciplinary teams to review the guideline and plan local implementation.[21]
• Centralise colon cancer surgery by defining the number, location and implementation timetable for designated cancer centres, and seek funding through routine service-planning processes.[16][22][23]
• Strengthen capacity through a rolling capital investment plan, coordinated consultant appointments, expanded radiographer and sonographer training, and a comprehensive cancer-services workforce plan.[24][25][19]
• Provide specialist support by ensuring access to stoma-care or clinical nurse specialists, psychological and social support, prehabilitation, patient-friendly information and appropriate palliative-care services.[17][14]
• Engage patients, advocacy organisations, charities and wider stakeholders in guideline development, practical care considerations, quality-of-life priorities and review processes.[26][27]
• Develop recommendations through systematic evidence searching, critical appraisal, evidence tables, economic assessment and structured judgement, with external expert review, conflict-of-interest management and National Clinical Effectiveness Committee quality assurance and endorsement processes.[28][29][30][27]
• Disseminate and support adoption through professional networks, national websites, communications, training, education, voluntary organisations and patient groups.[21]
• Monitor implementation and patient outcomes through regular National Cancer Control Programme reviews with cancer centres and Hospital Groups, clinical audit, service-planning discussions and National Cancer Strategy indicators, including complete surgical centralisation and the proportion of patients receiving specialist palliative care.[3][18][19][31]
• Review the guideline three years after publication and conduct periodic literature surveillance, with interim updates subject to National Clinical Effectiveness Committee approval.[27][21]

Monitoring & Evaluation

The guideline establishes a national implementation, monitoring and review approach for colon cancer care, centred on clinical governance, multidisciplinary decision-making, audit, performance review and periodic evidence surveillance.[21][3]Corporate responsibility for implementation rests with hospital Chief Executive Officers, General Managers and Clinical Directors, while multidisciplinary team members are accountable for recommendations within their professional disciplines.[1][2]

• Require hospital multidisciplinary teams and senior management to review the guideline, develop implementation plans with actions, leads, timeframes and expected outcomes, and support staff to implement relevant recommendations.[21]
• Monitor service performance through quarterly National Cancer Control Programme meetings with cancer centres, regular reviews with Hospital Groups and senior management, and discussions of performance data, improvement plans, staffing, resources and service development.[21][3]
• Audit guideline implementation and patient outcomes using the audit criteria in Appendix 8, with clinical audit following planning, standards selection, performance measurement, improvement and sustainment stages.[3][19]
• Use clinical audit, shared good practice and problem solving through the Colorectal Cancer Clinical Leads Group to support oversight and local service improvement.[5][21]
• Monitor centralisation through Cancer Strategy Key Performance Indicator 11, defined as complete centralisation of cancer surgical services, and monitor specialist palliative care access through Key Performance Indicator 19.[23][8][31]
• Use specified clinical quality measures, including a laboratory median of at least 12 lymph nodes examined following colon cancer surgery, alongside pathological assessment requirements and multidisciplinary review of selected diagnostic and treatment decisions.[9][32]
• Verify equipment access through completion of the capital investment plan, verify trained-staff access through training provision and records, and verify workforce delivery through evidence that staff are in post and the workforce assessment is completed.[24][25]
• Conduct periodic literature surveillance through the National Cancer Control Programme and consider the guideline for review three years after its December 2020 publication; subject interim and review-related updates to National Clinical Effectiveness Committee approval and publish update notifications online.[27][21]
• Maintain evidence assurance through systematic appraisal, external expert review, stakeholder consultation, documented amendments, conflict-of-interest management and recommendation grading based on evidence quality, directness and potential for further research to change conclusions.[2][30][27]

The source does not define a comprehensive set of quantitative implementation targets, indicator specifications, reporting intervals or surveillance methods beyond the stated audits, key performance indicators, verification measures, multidisciplinary outcome reporting and review arrangements.[16][24][8]

Costing & Financing

Implementation requires operational expenditure, workforce development and capital planning, although several staff and revenue costs remain unconfirmed pending surgical centralisation and workforce planning.[17][33][24]Total expected operational costs are reported as €905,410 and €2,716,230 in the implementation cost tables.[17][33][24]

• Fund diagnostic equipment through the Health Service Executive service-planning process and develop a rolling capital investment plan with the National Cancer Control Programme, Health Service Executive directorates and the Department of Health.[24][22]
• Plan workforce investment across radiology, surgery, pathology, palliative care, nursing, laboratory science and multidisciplinary-team data-management functions; final staffing costs await centralisation and workforce-planning outcomes.[33][24][25]
• Provide for imaging-related operational costs, including hepatocyte-specific contrast-enhanced magnetic resonance imaging and computed tomography colonography; positron emission tomography-computed tomography costs are to be determined because activity volumes and annual costs are unknown.[34]
• Seek funding for centralisation of cancer surgery through normal service-planning processes, while designated cancer centres require investment in infrastructure, facilities, personnel and programmes.[16][22][35]
• Apply budget-impact and economic evidence review methods, including appraisal of economic studies and consideration of resource implications and health-system impact when developing recommendations.[29][30][36]
• Interpret international cost-effectiveness evidence cautiously, as differences in thresholds, discounting, analytical perspective and health-sector costing limit direct transferability to Ireland; no explicit Irish threshold exists for non-drug interventions, although €45,000 per quality-adjusted life year is conventionally considered cost-effective.[36]

Economic evidence suggests that some minimally invasive and endoscopic approaches may reduce costs or improve value, but these study-specific findings do not constitute an implementation budget or funding allocation.[37][38][39][40]Funding gaps, detailed resource mobilisation arrangements and wider economic assumptions are not specified.[17][34][35]